Quest Diagnostics, a Secaucus-based provider of diagnostic information services, announced Thursday it has acquired PhenoPath, a Seattle-based provider of specialized anatomic pathology and related services.
PhenoPath provides AP, molecular oncology and other services that will improve Quest’s Advanced Diagnostics portfolio.
“Our acquisition of PhenoPath delivers on our accelerate growth strategy for advanced diagnostics,” Steve Rusckowski, Chairman, CEO and president, Quest Diagnostics, said. “PhenoPath has a strong record of innovation, and provides several capabilities that complement and extend our own, particularly in pathology and molecular oncology. It also deepens our presence in the Pacific Northwest.”
Under terms of the deal, PhenoPath will operate as part of AmeriPath, a wholly-owned business of Quest Diagnostics.
Financial and other terms of the deal were not disclosed.